Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA interference ...

The placebo-controlled study is aimed at assessing the safety and efficacy of zodasiran in adults and adolescents with HoFH.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company’s global Phase ...

The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

Arrowhead Pharmaceuticals, Inc. today announced that it has completed enrollment in SHASTA -3, SHASTA -4, and MUIR-3, the company’ s global Phase 3 clinical studies designed to support ...

PASADENA, Calif., June 23, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company’s global Phase 3 ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mereo Biopharma Group Plc (MREO – Research Report), Amgen (AMGN – Research Rep ...

Arrowhead Pharmaceuticals, Inc. (ARWR) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions ...

Read about Arrowhead Pharmaceuticals Inc (ARWR:XNAS) stock and today's latest news and financial updates.